Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | EVP, Head of U.S. Commercial | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,940 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Sale · Disposed 1,093 · Balance 63,940 |
| Common StockSEC Table I · non-derivative | Direct | 71,797 |
Reported balance
After 2026-07-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 7,857 · Balance 71,797 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-07-16 | Direct | 19,643 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Grant · Acquired 19,643 · Balance 19,643 F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.65 · Expires 2036-07-15 | Direct | 33,918 |
Reported balance
After 2026-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-16 · Grant · Acquired 33,918 · Balance 33,918 F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 33,918 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 4 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,918 Underlying: Common Stock · 33,918 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 19,643 | $0.00 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · derivative · entry 3 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,643 Underlying: Common Stock · 19,643 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 2 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,797 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,093 | $115.01 | $125,705.93 |
DisclosureSEC source: 0002050035-26-000011 · wk-form4_1784578149.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,940 Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,099 | $115.09 | $126,483.91 |
DisclosureSEC source: 0002050035-26-000009 · wk-form4_1784232398.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,033 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 63,940 shares of common stock issuable pursuant to previously reported RSUs that have not vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 14,237 | $0.00 Strike: $106.21 | $0.00 |
DisclosureSEC source: 0002050035-26-000004 · wk-form4_1769029568.xml · derivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,237 Underlying: Common Stock · 14,237 shares Expires 2036-01-15 F1 · derivative.exercise_date: Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:03 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,856 | $109.07 | $1,184,063.92 |
DisclosureSEC source: 0002050035-26-000002 · wk-form4_1767906216.xml · nonDerivative · entry 2 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,132 F2 · balance_after: This includes an aggregate of 66,132 shares of common stock issuable pursuant to previously reported RSUs that have not vested. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:03 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 8,264 | $106.66 | $881,438.24 |
DisclosureSEC source: 0002050035-26-000002 · wk-form4_1767906216.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,988 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 19,735 | $0.00 Strike: $68.25 | $0.00 |
DisclosureSEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · derivative · entry 3 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,735 Underlying: Common Stock · 19,735 shares Expires 2035-07-14 F4 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 21,923 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · derivative · entry 2 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,923 Underlying: Common Stock · 21,923 shares Expires 2028-07-15 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:04 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 8,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000090 · wk-form4_1752782653.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,252 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 85,252 shares of common stock issuable pursuant to previously reported RSUs that have not vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:42 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 27,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000068 · wk-form4_1751488914.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,483 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years from the vesting commencement date of January 6, 2025. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the June 30, 2025 grant, this includes an aggregate of 76,483 shares of common stock issuable pursuant to previously reported RSUs that have not vested. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 48,671 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000009 · wk-form4_1736370662.xml · nonDerivative · entry 1 Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,671 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes the January 6, 2025 aggregate grant of 48,671 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.